References
1. Davis PB, Drumm M, Konstan MW. State of the art: CF. Am J Resp Crit Care Med 1996;154:1229–1256.
2. Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158–163.
3. Burns JL, Saiman L. Burkholderia cepacia infections in cystic fibrosis. Pediatr Infect Dis J1999;18:155–156.
4. Olivier KN, Yankaskas JR, Knowles MR. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin Respir Infect 1996;11:272–284.
5. Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Micro Rev1996;9:177–215.
6. Kourbeti IS, Maslow MJ. Nontuberculous mycobacteria infections of the lung. Curr Infect Dis Rep2000;2:193–200.
7. Ebert DL, Olivier KN. Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med2002;23:655–663.
8. Hjelte L, Petrini B, Kallenius G, et al. Prospective study of mycobacterial infections in patients with CF. Thorax 1990;45:397–400.
9. Hjelt K, Hojlyng N, Howitz P, et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with CF. Scand J Infect Dis 1994;26:569–576.
10. Hodson ME. Bacterial infection in CF: special reference to mycobacteria and Burkholderia cepacia. Pediatr Pulmonol Suppl 1995;11:66–67.
11. Fauroux B, Delaisi B, Clement A, et al. Mycobacterial lung disease in CF: a prospective study.Pediatr Infect Dis J 1997;16:354–358.
12. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria, I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167:828–834.
13. Whittier S, Hopfer RL, Knowles MR, et al. Improved recovery of mycobacteria from respiratory secretions of patients with CF. J Clin Microbiol 1993;31:861–864.
14. Whittier S, Olivier K, Gilligan P, et al. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from CF patients. J Clin Microbiol 1997;35:2706–2708.
15. Bange FC, Kirschner P, Bottger EC. Recovery of mycobacteria from patients with CF. J Clin Microbiol 1999;37:3761–3762.
16. Official statement of the American Thoracic Society approved by the Board of Directors, Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med1997;156:S1–25.
17. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am Rev Respir Dis 1993;147:1271–1278.
18. Peloquin CA. Serum concentrations of the antimycobacterial drugs. Chest 1998;113:1154–1155.
19. Wallace RJ, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149:1335–1341.
20. Wallace RJ, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. Am J Respir Crit Care Med 1996;153:1762–1772.
21. Cullen AR, Cannon CL, Mark EJ, et al. Mycobacterium abscessus infection in CF. Am J Respir Crit Care Med 2000;161:641–645.
22. Colin AA. Eradication of Mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol 2000;30:267–268.
23. Brown-Elliot BA, Wallace RJ Jr. Clarithromycin resistance in Mycobacterium abscessus. J Clin Microbiol 2001;39:2745–2746.
24. Tebas P, Sultan F, Wallace RJ Jr, et al. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis 1995;20:443–444.
25. Wallace RJ Jr, Meier A, Brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother1996;40:1676–1681.
26. Wallace RJ, Tanner D, Brennan PJ, et al. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993;119:482–486.
27. Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of Linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45:764–767.
28. Brown-Elliott BA, Wallace RJ Jr, Blinkhorn R, et al. Successful treatment of disseminatedMycobacterium chelonae infection with linezolid. Clin Infect Dis 2001;33:1433–1434.
29. Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999;160:1611–1616.
30. Sanguinetti M, Ardito F, Fiscarelli E, et al. Fatal pulmonary infection due to multidrug-resistantMycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001;39:816–819.
31. Fairhurst RM, Kubak BM, Shpiner RB, et al. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant 2002;21:391–394.